Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.

Biotechnology

Mozart Therapeutics

Katie Fanning

Russ Hawkinson

Jennifer More

Courtney Crane

Kristine Swiderek

The Research and Development team at Mozart Therapeutics spearheads the innovation and advancement of disease-modifying CD8 Treg modulators for autoimmune and inflammatory diseases. This team conducts cutting-edge research, designs and implements experiments, and collaborates to translate scientific discoveries into therapeutic candidates. They work to advance the understanding of the CD8 T cell network and drive the development of a therapeutic pipeline aimed at restoring long-term immune balance.

Research and Development

Directors Team

Leadership Team

Research and Development

About

Team members

Other teams at Mozart Therapeutics

Directors Team

Leadership Team